Vyant Bio Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Public

  • Employees
  • 85

Employees

  • Investments
  • 5

  • Share Price
  • $0.14
  • (As of Wednesday Closing)

Vyant Bio General Information

Description

Vyant Bio Inc incorporates biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The company's platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. The majority of revenue is earned in the United States.

Contact Information

Formerly Known As
Cancer Genetics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 2 Executive Campus, 2370 State Route 70 West
  • Suite 310
  • Cherry Hill, NJ 08002-4102
  • United States
+1 (201) 000-0000

Vyant Bio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vyant Bio Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.14 $0.18 $0.14 - $1.70 $1.14M 6.33M 33.65 -$3.87

Vyant Bio Financials Summary

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV (2,914) (2,914) 16,933
Revenue 666 666 1,148 867
EBITDA (15,057) (15,057) (17,149) (7,005)
Net Income (22,690) (22,690) (40,859) (8,650)
Total Assets 15,205 15,205 37,636 4,049
Total Debt 2,196 2,196 1,197 7,952
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vyant Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vyant Bio‘s full profile, request access.

Request a free trial

Vyant Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vyant Bio‘s full profile, request access.

Request a free trial

Vyant Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vyant Bio Inc incorporates biology and data science to improve drug discovery for complex neurodevelopmental and neurode
Biotechnology
Cherry Hill, NJ
85 As of 2022
000.00
000000000 000.00

000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non p
0000000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

000000

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000 000000000
Cambridge, MA
000 As of 0000
00000
0000000000.
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vyant Bio Competitors (51)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
Codiak BioSciences Formerly VC-backed Cambridge, MA 000 00000 0000000000.
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
Fore Bio Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
Ayala Pharmaceuticals Corporation Wilmington, DE 00 00000 00000000
You’re viewing 5 of 51 competitors. Get the full list »

Vyant Bio Patents

Vyant Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160130665-A1 Prognostic methods and systems for chronic lymphocytic leukemia Inactive 11-Nov-2014 0000000000
US-20140235458-A1 Methods and tools for the diagnosis and prognosis of urogenital cancers Inactive 15-Feb-2013 0000000000
CA-2901543-A1 Methods and tools for the diagnosis and prognosis of urogenital cancers Inactive 15-Feb-2013 0000000000
EP-2956551-A1 Methods and tools for the diagnosis and prognosis of urogenital cancers Inactive 15-Feb-2013 0000000000
US-20150031017-A1 Methods for detecting human papillomavirus-assocated cancers Active 08-Sep-2010 C12Q1/708
To view Vyant Bio’s complete patent history, request access »

Vyant Bio Executive Team (16)

Name Title Board Seat Contact Info
Andrew LaFrence President, Chief Executive Officer & Chief Financial Officer
You’re viewing 1 of 16 executive team members. Get the full list »

Vyant Bio Board Members (11)

Name Representing Role Since
Geoffrey Harris Ph.D Self Board Member 000 0000
Howard McLeod Ph.D Self Board Member 000 0000
Joanna Horobin Vyant Bio Board Member 000 0000
John Roberts Vyant Bio Board Member 000 0000
Raju Chaganti Ph.D Vyant Bio Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Vyant Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vyant Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vyant Bio‘s full profile, request access.

Request a free trial

Vyant Bio Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
StemoniX 30-Mar-2021 0000000000 000.00 Biotechnology 0000 0000
VivoPharm 15-Aug-2017 0000000000 00.00 Other Pharmaceuticals and Biotechnology 00000 000
Response Genetics 09-Oct-2015 0000000000 000.00 Diagnostic Equipment 000000 00
Gentris 16-Jul-2014 0000000000 00.000 Practice Management (Healthcare) 00000 000
Cancer Genetics India 15-May-2014 Merger/Acquisition 00.00 Laboratory Services (Healthcare) 00000 000
To view Vyant Bio’s complete acquisitions history, request access »

Vyant Bio Subsidiaries (1)

Company Name Industry Location Founded
StemoniX Biotechnology Maple Grove, MN 0000
To view Vyant Bio’s complete subsidiaries history, request access »

Vyant Bio ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Software & Services

Industry

Rank

Percentile

Internet Software and Services

Subindustry

Rank

Percentile

To view Vyant Bio’s complete esg history, request access »

Vyant Bio Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
StemoniX 30-Mar-2021 000000000000000000 000.00 Completed
  • 00000 000
VivoPharm 15-Aug-2017 000000000000000000 00.00 Completed
  • 00000 000
Cancer Genetics India 15-May-2014 Merger/Acquisition 00.00 Completed
To view Vyant Bio’s complete exits history, request access »

Vyant Bio FAQs

  • When was Vyant Bio founded?

    Vyant Bio was founded in 1999.

  • Who is the CEO of Vyant Bio?

    Andrew LaFrence is the CEO of Vyant Bio.

  • Where is Vyant Bio headquartered?

    Vyant Bio is headquartered in Cherry Hill, NJ.

  • What is the size of Vyant Bio?

    Vyant Bio has 85 total employees.

  • What industry is Vyant Bio in?

    Vyant Bio’s primary industry is Biotechnology.

  • Is Vyant Bio a private or public company?

    Vyant Bio is a Public company.

  • What is the current stock price of Vyant Bio?

    As of 03-Jan-2024 the stock price of Vyant Bio is $0.14.

  • What is the current market cap of Vyant Bio?

    The current market capitalization of Vyant Bio is $1.14M.

  • What is Vyant Bio’s current revenue?

    The trailing twelve month revenue for Vyant Bio is $666K.

  • Who are Vyant Bio’s competitors?

    Dynavax Technologies, Codiak BioSciences, Inovio Pharmaceuticals, Fore Bio, and Ayala Pharmaceuticals are some of the 51 competitors of Vyant Bio.

  • What is Vyant Bio’s annual earnings per share (EPS)?

    Vyant Bio’s EPS for 12 months was -$3.87.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »